Key Highlights
- Charles River and Wheeler Bio announce a strategic agreement to provide early-stage biotech companies with a streamlined path to clinical trials.
- The partnership integrates Charles River’s extensive experience in antibody discovery and Wheeler’s Portable CMC® platform, reducing the complexity of preclinical to clinical transition.
- Wheeler Bio’s state-of-the-art facilities in Oklahoma City and satellite lab in Waltham, MA, enhance the offering with advanced process development and CGMP capabilities.
Source: Business Wire
Notable Quotes
- “We are thrilled to provide Charles River clients with access to Wheeler’s innovative Portable CMC® platform, which will optimize their workflows and ultimately bring new treatments to patients faster.” – Julie Frearson, Corporate Senior Vice President, Chief Scientific Officer at Charles River
- “Wheeler is excited to expand our relationship with Charles River and to link with their discovery organization…Our combined sales teams look forward to co-promoting these services for the benefit of our biotech partners and their pipelines towards clinical impact.” – Jesse McCool, CEO and Co-Founder at Wheeler Bio
SoHC's Take
This strategic alliance between Charles River and Wheeler Bio represents a significant leap forward in the biotechnology industry’s ability to efficiently and effectively move from discovery to clinical trials. By combining Charles River’s proven expertise in antibody discovery and safety analytics with Wheeler Bio’s innovative Portable CMC® platform, this partnership offers a unique, integrated solution. It not only simplifies the journey from concept to commercialization but also promises to accelerate the delivery of new treatments to patients. The collaboration is a testament to the evolving landscape of drug development, where efficiency, expertise, and advanced technology converge to streamline the path to clinical success. This alliance is poised to set a new standard in the industry, demonstrating the power of collaborative innovation in overcoming translational challenges and advancing healthcare.
